<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090137</url>
  </required_header>
  <id_info>
    <org_study_id>GN18CA427</org_study_id>
    <nct_id>NCT05090137</nct_id>
  </id_info>
  <brief_title>Quantifying Congestion by Ultrasound</brief_title>
  <acronym>QUEST-HF</acronym>
  <official_title>Quantifying Interstitial and Intravascular Fluid Accumulation by Ultrasound Following Temporary Suspension of Loop Diuretics in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine the feasibility of identifying and quantifying changes in&#xD;
      interstitial and intravascular congestion by imaging in participants with heart failure. The&#xD;
      investigators will either continue or temporarily suspend both loop diuretics and&#xD;
      mineralo-corticoid antagonists (MRA) for 48 hours in participants with heart failure that is&#xD;
      both stable and mild and compare measurements of interstitial (B-lines) and intra-vascular&#xD;
      fluids (IVC and JV diameter and renal venous flow) by ultrasound and, in a subset of&#xD;
      participants without contra-indications, by cardiac MRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in ultrasound markers or congestion following continuation or suspension of diuretics for 48 hours.</measure>
    <time_frame>at baseline</time_frame>
    <description>Differences in interstitial (B-lines) and intravascular (IVC and JV diameter, and renal venous flow) congestion by ultrasound in patients with heart failure following continuation or suspension of diuretics for 48 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The acute variation in interstitial and intravascular congestion on imaging tests following administration of diuretics.</measure>
    <time_frame>up to 3 hours</time_frame>
    <description>The acute variation in interstitial (B-lines) and intravascular (inferior vena cava, jugular vein diameter and renal venous flow) congestion on imaging tests following administration of diuretics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The acute variation in biomarkers of congestion, inflammation and myocardial injury following administration of diuretics.</measure>
    <time_frame>at 3 hours</time_frame>
    <description>The acute variation in biomarkers of congestion (NT-proBNP), inflammation (HsCRP) and myocardial injury (Troponin) following administration of diuretics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Diuretic cessation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be asked to withhold their diuretic therapy (loop diuretics and mineralocorticoid receptor antagonists) 48 hours prior to visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual diuretic regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will take their usual diuretic regimen prior to study visit. At least one week is required between cross-over visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diuretics</intervention_name>
    <description>As per group descriptions</description>
    <arm_group_label>Diuretic cessation</arm_group_label>
    <arm_group_label>Usual diuretic regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of heart failure&#xD;
&#xD;
          -  Plasma NT-proBNP &gt;125ng/L or BNP &gt;35 ng/l&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;50% on prior imaging test&#xD;
&#xD;
          -  Treated routinely with a daily dose of loop diuretic&#xD;
&#xD;
          -  Receiving other guideline-indicated therapy for heart failure&#xD;
&#xD;
          -  Willing to sign the informed consent form&#xD;
&#xD;
          -  Greater than 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic Kidney Disease Stage 4 or worse (eGFR &lt;30 mL/min/1.73 mÂ²)&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Significant valve disease (investigators opinion)&#xD;
&#xD;
          -  Breathlessness or chest pain at rest or minor exertion&#xD;
&#xD;
          -  Patients unable to lie flat&#xD;
&#xD;
          -  Patients deemed too unstable to miss treatment with diuretics for 48 hours&#xD;
&#xD;
          -  Patients taking part in another interventional trial&#xD;
&#xD;
          -  Any other concomitant condition that in the opinion of the investigator would not&#xD;
             allow a safe participation in the study (ie:-pregnancy, significant frailty)&#xD;
&#xD;
          -  Patients unwilling or unable to consent&#xD;
&#xD;
          -  For patients willing to undergo MRI; contraindication to MRI including claustrophobia,&#xD;
             metalworkers, and intra-orbital or intracranial metal (eg:- stents), and non-MRI&#xD;
             compliant device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierpaolo Pellicori, MD, FESC</last_name>
    <phone>+44 0141 330 4744</phone>
    <email>pierpaolo.pellicori@glasgow.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Maureen Travers</last_name>
    </contact>
    <investigator>
      <last_name>Pierpaolo Pellicori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

